Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Episcleral Celecoxib for Macular Edema and Inflammatory Disorders
NCT04120636Phase 1Active, not recruiting
- Sponsor
- Targeted Therapy Technologies
- Start
- Mar 2021
- Primary completion
- Jun 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of celecoxib in macular edema and Acute Posterior Multifocal Placoid Pigment Epitheliopathy (APMPPE), sponsored by Targeted Therapy Technologies. Primary endpoint: Ocular safety assessment at 12 Months. Started Mar 2021; status: active, not recruiting.
02
Drugs
celecoxib
03
Conditions
macular edemaAcute Posterior Multifocal Placoid Pigment Epitheliopathy (APMPPE)
Beyond the preview
Go deeper on NCT04120636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04120636.